cholangiocarcinoma

Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively).

Micromelin exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100.

Murrangatin may be a valuable anti-tumor-promoting agent, it can significantly inhibit Epstein-Barr virus early antigen (EBV-EA) activation, and preserve the high viability of Raji cells, it also exhibits cytotoxicity against cholangiocarcinoma cell line,

Infigratinib monohydrate, also known as, BGJ398 monohydrate or NVP-BGJ398 monohydrate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib monohydrate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.

Murralongin exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100.

Raddeanin A (NSC-382873) has moderate inhibitory activity against histone deacetylases (HDACs). Raddeanin A has high antiangiogenic potency, antitumor activity.

Triphen Diol, a phenol diol derivative, exhibits potent anticancer properties against pancreatic cancer and cholangiocarcinoma, efficiently inducing pancreatic cell apoptosis via both caspase-mediated and caspase-independent mechanisms.

Minumicrolin is a plant growth inhibitor against the 2nd leaf sheath elongation of rice seedlings. Murrangatin exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100, it might be valuable anti-tumor-promoting agents. Minumicrolin shows mild butyrylcholinesterase inhibition activity.

Derazantinib is a multi-kinase inhibitor with pan-FGFR activity which has shown preliminary therapeutic activity against FGFR2 fusion-positive intrahepatic cholangiocarcinoma (iCCA). Derazantinib dihydrochloride is a salt of Derazantinib.

Infigratinib mesylate, also known as, BGJ398 mesylate or NVP-BGJ398 mesylate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib mesylate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.

Infigratinib acetate, also known as, BGJ398 acetate or NVP-BGJ398 acetate, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib acetate was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.